Karyopharm Therapeutics Inc. (KPTI) · Nov 5, 2026 · Delisting

Karyopharm delisting confirms Nasdaq exit as bankruptcy deepens

Nasdaq delisting — Nasdaq trading suspended November 11; existing equity expected to have no value

Karyopharm’s delisting filing makes the bankruptcy consequences explicit: Nasdaq trading ends November 11, with equity expected to have no value.

Karyopharm is a commercial-stage cancer biotech built around selinexor/XPOVIO, but it is now operating under Chapter 11 while pursuing a court-supervised restructuring and asset transaction. This filing is mainly confirmation, not a fresh business shock. Nasdaq has formally decided to delist the company because of the bankruptcy, and Karyopharm will not appeal. 〔0〕 The bankruptcy and the proposed restructuring were already disclosed on November 2, so the direction of travel was known; the new information is the firm suspension date and OTC mechanics.

The equity outcome is now stated as close to zero, not merely left uncertain. Nasdaq trading is scheduled to stop at the opening of business on November 11, 2026, after which the shares are expected to trade over the counter under KPTIQ. 〔1〕 More importantly, the company says its existing equity securities are expected to have no value and holders are expected to suffer a complete loss. 〔2〕 That is consistent with the prepackaged plan already filed, which provides no distribution to common or Series A preferred holders.

The business question has shifted from public-market execution to bankruptcy-court execution. The meaningful next variable is whether the Chapter 11 plan and proposed Ayrmid-led transaction are approved and completed; the delisting itself does not preserve or improve the operating business. The OTC listing may keep a trading venue open, but the filing explicitly warns that trading may not commence or continue and may have little relationship to any eventual recovery.

Bottom line: This is a mostly anticipated but still unequivocally negative confirmation: Karyopharm is leaving Nasdaq, while the company itself expects existing equity to be wiped out. The filing adds procedural finality more than new business deterioration.

What to watch next

Court approval of the Chapter 11 plan and Ayrmid transaction

Original filing on SEC EDGAR

More Karyopharm Therapeutics Inc. news

Karyopharm delisting confirms Nasdaq exit as bankruptcy deepens | KPTI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.